Compare NBIX & EQX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | EQX |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.3B |
| IPO Year | 1996 | 2018 |
| Metric | NBIX | EQX |
|---|---|---|
| Price | $130.61 | $15.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 1 |
| Target Price | ★ $180.82 | $17.00 |
| AVG Volume (30 Days) | 901.1K | ★ 9.7M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.10% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $22.85 | $95.14 |
| Revenue Next Year | $10.36 | $11.73 |
| P/E Ratio | ★ $27.09 | $137.41 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $97.30 | $5.64 |
| 52 Week High | $160.18 | $18.96 |
| Indicator | NBIX | EQX |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 57.45 |
| Support Level | $124.29 | $13.54 |
| Resistance Level | $136.23 | $17.40 |
| Average True Range (ATR) | 4.29 | 0.69 |
| MACD | -0.08 | 0.29 |
| Stochastic Oscillator | 59.64 | 95.55 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.